VICTORION-2 PREVENT
A randomized double-blind, placebo controlled, multicenter trial, assessing the impact of Inclisiran on major adverse cardiovascular events in patients with established cardiovascular disease
- Stadium
- followup
- Middel
- Inclisiran
- Populatie
- ASCVD
- Fase
- III
- First Patient In
- 25 februari 2022
- Last Patient In
- 21 augustus 2023
- Last Patient Last Visit
- 15 maart 2027
National Lead
prof. dr. J. W. Jukema
Cardioloog
Studiedirecteur
